Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Nonpeptide GnRH antagonists claimed by Merck & Co.

Feb. 9, 1999

New photoactive agents in development at QLT and U. of British Columbia

Feb. 9, 1999

Hughes Institute enters licensing agreement for anticancer drug development

Feb. 9, 1999

Boston Life Sciences identifies a second antiangiogenic molecule

Feb. 8, 1999

Orphan Medical's Busulfex Injection approved in U.S.

Feb. 8, 1999

Lorus Therapeutics announces preclinical data on anticancer compound

Feb. 8, 1999

Aronex's NDA for Atragen accepted for review

Feb. 5, 1999

Vitaxin proceeds to phase II

Feb. 5, 1999

First phase I clinical trials commence with NX-211

Feb. 4, 1999

Preclinical study of TRAIL points to promise as antitumor agent

Feb. 4, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...